- 动物研究(PDF.2 MB)
- Clinical study transparency (PDF 0.2 MB)
- Medicines for Patients with Rare 疾病 (PDF 0.2 MB)
- 审判后访问(PDF.1 MB)
- Pre-Approval 访问 to bwin中国制药 产品 through MAPs (PDF 0.3 MB)
- Responsible 临床试验 (PDF 0.1 MB)
- bwin中国制药 Commitment to Diversity in 临床试验 (PDF 0.2 MB)
- bwin中国制药 Position on Investigator Initiated Trials (IITs) and Investigator Initiated 研究 (IIRs) (PDF 0.2 MB)
职位
才能找到长久, sustainable solutions to global health challenges, we need to engage in constructive discussions and be transparent about our views. We engage in policy debates and share the company’s perspective on issues including access to healthcare, 道德, R&D and quality of medicines, striving for open and constructive interaction.
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.